Compare CRVL & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRVL | TARS |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 1995 | 2020 |
| Metric | CRVL | TARS |
|---|---|---|
| Price | $71.70 | $77.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $89.00 |
| AVG Volume (30 Days) | 147.1K | ★ 653.8K |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.94 | ★ 48.21 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $958,527,000.00 | $451,360,000.00 |
| Revenue This Year | N/A | $56.43 |
| Revenue Next Year | N/A | $30.19 |
| P/E Ratio | $114.02 | ★ N/A |
| Revenue Growth | 7.03 | ★ 146.71 |
| 52 Week Low | $44.83 | $53.89 |
| 52 Week High | $80.79 | $91.53 |
| Indicator | CRVL | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 64.93 | 52.19 |
| Support Level | $65.62 | $60.95 |
| Resistance Level | N/A | $79.10 |
| Average True Range (ATR) | 1.87 | 3.70 |
| MACD | 0.06 | -1.01 |
| Stochastic Oscillator | 95.01 | 17.02 |
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.